Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. Daratumumab is approved as a single agent by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). According to Dr Palumbo, the submission for the three agent submission will be started and it should be available within 12-18 months.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: When will the daratumumab triplet combination be approved for multiple myeloma?
